×

Peptide therapeutics and methods for using same

  • US 10,293,020 B2
  • Filed: 06/24/2014
  • Issued: 05/21/2019
  • Est. Priority Date: 06/27/2013
  • Status: Active Grant
First Claim
Patent Images

1. A composition comprising the mitochondria penetrating peptide (MPP) Cha-Arg-Cha-Lys-NH2 alone or in combination with one or more aromatic-cationic peptides selected from the group consisting of:

  • 2′

    6′

    -Dmp-D-Arg-2′

    6′

    -Dmt-Lys-NH2;

    2′

    ,6′

    -Dmt-D-Arg-Phe-Lys-NH2;

    2′

    6′

    -Dmp-D-Arg-Phe-Lys-NH2;

    2′

    6′

    -Dmt-D-Arg-PheOrn-NH2;

    2′

    6′

    -Dmt-D-Arg-Phe-Ahp(2-aminoheptanoicacid)-NH2;

    2′

    6′

    -Dmt-D-Arg-Phe-Lys-NH2;

    2′

    6′

    -Dmt-D-Cit-PheLys-NH2;

    Ala-D-Phe-D-Arg-Tyr-Lys-D-Trp-His-D-Tyr-Gly-Phe;

    Arg-D-Dmt-Arg-NH2;

    Arg-D-Dmt-Lys-NH2;

    Arg-D-Dmt-NH2;

    Arg-D-Leu-D-Tyr-Phe-Lys-Glu-D-Lys-Arg-D-Trp-Lys-D-Phe-Tyr-D-Arg-Gly;

    Arg-D-Tyr-Arg-NH2;

    Arg-D-Tyr-Lys-NH2;

    Arg-D-Tyr-NH2;

    Asp-Arg-D-Phe-Cys-Phe-D-Arg-D-Lys-Tyr-Arg-D-Tyr-Trp-D-His-Tyr-D-Phe-Lys-Phe;

    Asp-D-Trp-Lys-Tyr-D-His-Phe-Arg-D-Gly-Lys-NH2;

    D-Arg-2′

    6′

    -Dmt-Lys-Phe-NH2;

    D-Arg-Arg-Dmt-Phe-NH2;

    D-Arg-Arg-Tyr-Phe-NH2;

    D-Arg-Cha-Lys-Cha-NH2;

    D-Arg-Cha-Lys-NH2;

    D-Arg-D-Dmt-NH2;

    D-Arg-Dmt-D-Lys-Phe-NH2;

    D-Arg-Dmt-Lys-Dmt-Lys-Met-NH2;

    D-Arg-Dmt-Lys-Dmt-Lys-Trp-NH2;

    D-Arg-Dmt-Lys-D-Phe-NH2;

    D-Arg-Dmt-Lys-NH2;

    D-Arg-Dmt-Lys-Phe-Lys-Met-NH2;

    D-Arg-Dmt-Lys-Phe-Lys-Trp-NH2;

    D-Arg-Dmt-Lys-Phe-Met-NH2;

    D-Arg-Dmt-Lys-Trp-NH2;

    D-Arg-Dmt-NH2;

    D-Arg-Dmt-Phe-NH2;

    D-Arg-D-Tyr-D-Lys-D-Phe-NH2;

    D-Arg-D-Tyr-Lys-Phe-NH2;

    D-Arg-D-Tyr-NH2;

    D-Arg-Phe-Lys-NH2;

    D-Arg-Trp-Lys-NH2;

    D-Arg-Trp-Lys-Trp-NH2;

    D-Arg-Tyr-D-Lys-Phe-NH2;

    D-Arg-Tyr-Lys-D-Phe-NH2;

    D-Arg-Tyr-Lys-NH2;

    D-Arg-Tyr-Lys-Phe-NH2;

    D-Arg-Tyr-NH2;

    D-Arg-Tyr-Phe-NH2;

    D-Dmt-Arg-NH2;

    D-Glu-Asp-Lys-D-Arg-D-His-Phe-Phe-D-Val-Tyr-Arg-Tyr-D-Tyr-Arg-His-Phe-NH2;

    D-His-Glu-Lys-Tyr-D-Phe-Arg;

    D-His-Lys-Tyr-D-Phe-Glu-D-Asp-D-Asp-D-His-D-Lys-Arg-Trp-NH2;

    Dmt-D-Arg-NH2;

    Dmt-D-Phe-Arg-Lys-NH2;

    Dmt-Lys-D-Phe-NH2;

    Dmt-Lys-NH2;

    Dmt-Lys-Phe-NH2;

    D-Nle-Cha-Ahe-Cha-NH2;

    D-Nle-Dmt-Ahe-Phe-NH2;

    D-Phe-D-Arg-D-Phe-D-Lys-NH2;

    D-Tyr-Arg-NH2;

    D-Tyr-Trp-Lys-NH2;

    Glu-Arg-D-Lys-Tyr-D-Val-Phe-D-His-Trp-Arg-D-Gly-Tyr-Arg-D-Met-NH2;

    Gly-Ala-Lys-Phe-D-Lys-Glu-Arg-Tyr-His-D-Arg-D-Arg-Asp-Tyr-Trp-D-His-Trp-His-D-Lys-Asp;

    Gly-D-Phe-Lys-His-D-Arg-Tyr-NH2;

    H-D-Arg(Nα

    Me)-Dmt(NMe)-Lys(Nα

    Me)-Phe(NMe)-NH2;

    H-D-Arg-Dmt-Lys(Nα

    Me)-Phe(NMe)-NH2;

    H-D-Arg-Dmt-Lys(Nα

    Me)-Phe-NH2;

    H-D-Arg-Dmt-Lys-Phe(NMe)-NH2;

    H-D-Arg-Dmt-Lys-Phe-Sar-Gly-Cys-NH2;

    H-D-Arg-Dmt-LysΨ

    [CH2-NH]Phe-NH2;

    H-D-Arg-Dmt-Ψ

    [CH2-NH]Lys-Phe-NH2;

    H-D-Arg-Dmt-Ψ

    [CH2-NH]Lys-Ψ

    [CH2-NH]Phe-NH2;

    H-D-Arg-Ψ

    [CH2-NH]Dmt-Lys-Phe-NH2;

    His-Tyr-D-Arg-Trp-Lys-Phe-D-Asp-Ala-Arg-Cys-D-Tyr-His-Phe-D-Lys-Tyr-His-Ser-NH2;

    Lys-D-Arg-Tyr-NH2;

    Lys-D-Gln-Tyr-Arg-D-Phe-Trp-NH2;

    Lys-Dmt-D-Arg-NH2;

    Lys-D-Phe-Arg-Dmt-NH2;

    Lys-D-Phe-Arg-Tyr-NH2;

    Lys-Phe-NH2;

    Lys-Trp-D-Tyr-Arg-Asn-Phe-Tyr-D-His-NH2;

    Met-Tyr-D-Arg-Phe-Arg-NH2;

    Met-Tyr-D-Lys-Phe-Arg;

    Phe-Arg-D-His-Asp;

    Phe-D-Arg-2′

    6′

    -Dmt-Lys-NH2;

    Phe-D-Arg-D-Phe-Lys-NH2;

    Phe-D-Arg-His;

    Phe-D-Arg-Lys-Trp-Tyr-D-Arg-His;

    Phe-D-Arg-Phe-D-Lys-NH2;

    Phe-D-Arg-Phe-Lys-NH2;

    Phe-D-Dmt-Arg-Lys-NH2;

    Phe-D-Tyr-Arg-Lys-NH2;

    Phe-Lys-Dmt-NH2;

    Phe-Phe-D-Tyr-Arg-Glu-Asp-D-Lys-Arg-D-Arg-His-Phe-NH2;

    Phe-Tyr-Lys-D-Arg-Trp-His-D-Lys-D-Lys-Glu-Arg-D-Tyr-Thr;

    Thr-Gly-Tyr-Arg-D-His-Phe-Trp-D-His-Lys;

    Thr-Tyr-Arg-D-Lys-Trp-Tyr-Glu-Asp-D-Lys-D-Arg-His-Phe-D-Tyr-Gly-Val-Ile-D-His-Arg-Tyr-Lys-NH2;

    Trp-D-Lys-Tyr-Arg-NH2;

    Trp-Lys-Phe-D-Asp-Arg-Tyr-D-His-Lys;

    Tyr-Asp-D-Lys-Tyr-Phe-D-Lys-D-Arg-Phe-Pro-D-Tyr-His-Lys;

    Tyr-D-Arg-NH2;

    Tyr-D-Arg-Phe-Lys-Glu-NH2;

    Tyr-D-Arg-Phe-Lys-NH2;

    Tyr-D-His-Phe-D-Arg-Asp-Lys-D-Arg-His-Trp-D-His-Phe;

    Tyr-D-Phe-Arg-Lys-NH2;

    Tyr-His-D-Gly-Met; and

    Val-D-Lys-His-Tyr-D-Phe-Ser-Tyr-Arg-NH2,and further comprising one or more additional active agents selected from the group consisting of cyclosporine, a cardiac drug, an anti-inflammatory, an anti-hypertensive drug, an antibody, an ophthalmic drug, an antioxidant, a metal complexer, and an antihistamine.

View all claims
  • 6 Assignments
Timeline View
Assignment View
    ×
    ×